Dupilumab Under Review for Chronic Spontaneous Urticaria
The FDA has accepted for review the sBLA for dupilumab for the treatment of patients with chronic spontaneous urticaria.
Stay updated with breaking news from Accessed March. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA has accepted for review the sBLA for dupilumab for the treatment of patients with chronic spontaneous urticaria.
The FDA has approved a new single-dose prefilled autoinjector of Udenyca (pegfilgrastim-cbqv), a biosimilar to Neulasta.
The FDA has cleared Abbott's FreeStyle Libre 2 and FreeStyle Libre 3 CGM system sensors for integration with automated insulin delivery systems.
The FDA has expanded the approval of Verzenio (abemaciclib) plus endocrine therapy removing the Ki-67 score requirement for patient selection.
The FDA has expanded the approval of Verzenio (abemaciclib) plus endocrine therapy, removing the Ki-67 score requirement for selection.